Think outside the cell: Rows announces desktop apps beta launch and triple user growth following bold billboards outside Microsoft and Google HQs
Backed by Lakestar, Accel, and Cherry Ventures, the beta version of Rows’ app for Windows…
Backed by Lakestar, Accel, and Cherry Ventures, the beta version of Rows’ app for Windows…
Technical validation of Speedcast SIGMA adds to the company’s credentials within the APN, including Advanced…
Maimonides Medical Center Adopts Revolutionary Technology That Quickly Distinguishes Bacterial and Viral Infections Maimonides is…
SOLANA BEACH, Calif., March 22, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a…
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company”…
GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
WOBURN, Mass., March 22, 2022 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the…
ANAHEIM, CA, March 22, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”),…
Outside research reports that immune checkpoint therapy of patients with ovarian clear cell carcinomas with…
POINT’s industry-leading radioisotope supply chain enabled company to avoid delays INDIANAPOLIS, March 22, 2022 (GLOBE…
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a clinical…
New Procedure Reimbursement Code Expected to Enhance Study Performance for Clinical Centers Participating in the…
Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds Initiated Phase…
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected…
Data demonstrate PHA121 to be a potent human bradykinin B2 receptor antagonist ZUG, Switzerland, March…
BOSTON, March 22, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company…
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a…
New Data Suggests Rapid, Sustained, and Consistent Migraine Relief with Trudhesa Treatment New Analysis Considers…
CUPERTINO, Calif., March 22, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva”…